登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)
APG-2449 in Patients With Advanced Solid Tumors
ClinicalTrials.gov 上登记的一项肺癌开放试验。牵头方不是本站收录的医院;本站收录的 5 家医院列为研究中心。
状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。
研究团队的联系方式见登记记录。本站不转递咨询。
列出这项试验的中国大陆医院 5
登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。
- 研究中心中山大学附属第一医院First Affiliated Hospital of Sun Yat-sen University广州医院页面
- 研究中心福建省肿瘤医院Fujian Cancer Hospital福州医院页面
- 研究中心福建医科大学附属协和医院Fujian Medical University Union Hospital福州医院页面
- 研究中心北京大学肿瘤医院Peking University Cancer Hospital北京医院页面
- 研究中心华中科技大学同济医学院附属协和医院Union Hospital武汉医院页面
登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心
来源:ClinicalTrials.gov 登记记录 NCT03917043,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配
这项试验的核对清单 7
只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。
展开清单(7 项)收起清单
18 岁 至 未注明;性别:不限
登记记录的入选字段
Subjects should provide fresh biopsy tumor tissue specimens prior to treatment.
入选标准第 14 条
Receiving concurrent anti-cancer therapy (chemotherapy, radiotherapy, immunotherapy, biologic therapy); or any investigational therapy within 28 days prior to the first dose of study drug.
排除标准第 1 条
Receiving TKI therapy within 8 days prior to the first dose of study drug.
排除标准第 2 条
Continuance of toxicities due to prior therapy that do not recover (CTCAE V5.0 Grade> 1).
排除标准第 3 条
ECOG Performance Status ≤ 1.
入选标准第 2 条
According to RECIST version 1.1, there is at least 1 measurable lesion.
入选标准第 4 条
Active symptomatic fungal, bacterial and/or viral infection including, but not limited to, active human immunodeficiency virus (HIV) or viral hepatitis (B or C).
排除标准第 7 条
Serum pregnancy test results of women of childbearing age were negative within 7 days before taking the first dose of study drug.
入选标准第 9 条
Female subjects who are pregnant or breastfeeding, or expecting to become pregnant during the study period.
排除标准第 9 条
勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:分期或严重程度(按试验的定义);化验:血常规、肝肾功能。
按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT03917043,读取于 2026年11月10日。
登记的入选标准
依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。
入选标准:Inclusion Criteria:
Dose exploration stage: non-small cell lung cancer diagnosed by histology and/or cytology and positive for ALK/ROS1 gene fusion (molecular diagnosis confirmed by the investigator) and malignant pleural mesothelioma, esophageal cancer and ovarian cancer. Kind of patients with advanced tumors. ECOG Performance Status ≤ 1. Expectation of life ≥ 3 months. According to RECIST version 1.1, there is at least 1 measurable lesion. Adequate hematologic and bone marrow functions. Adequate renal and liver function. Normal cardiac function. Brain metastases with clinically controlled neurologic symptoms. Serum pregnancy test results of women of childbearing age were negative within 7 days before taking the first dose of study drug. Men, women of childbearing age (postmenopausal women must have been menopausal for at least 12 months before they can be considered infertile) and their partners voluntarily take the study drug for at least 30 days after signing the informed consent form and taking the study drug as deemed effective by the investigator Contraceptive measures Ability to understand and willingness to sign a written informed consent form Subjects must be willing and able to complete the research procedures and follow-up inspections. Subjects are required to provide fresh (for recurrent subjects only) or archived tumor tissue samples from within 28 days prior to treatment. If none of these specimens are available, they may be included after consultation with the sponsor. Subjects should provide fresh biopsy tumor tissue specimens prior to treatment.排除标准:Exclusion Criteria:
Receiving concurrent anti-cancer therapy (chemotherapy, radiotherapy, immunotherapy, biologic therapy); or any investigational therapy within 28 days prior to the first dose of study drug. Receiving TKI therapy within 8 days prior to the first dose of study drug. Continuance of toxicities due to prior therapy that do not recover (CTCAE V5.0 Grade> 1). Has difficulty in swallowing, absorbing barrier, or other diseases blocking APG-2449' taken. Obvious cardiovascular disease history. Failure to recover adequately, as judged by the investigator, from prior surgical procedures. Patients who have had major surgery within 28 days from study entry, and patients who have had minor surgery within 14 days of study entry. Active symptomatic fungal, bacterial and/or viral infection including, but not limited to, active human immunodeficiency virus (HIV) or viral hepatitis (B or C). Known allergies to study drug ingredients or their analogs. Female subjects who are pregnant or breastfeeding, or expecting to become pregnant during the study period. According to the judgment of the investigator or sponsor, any symptoms or disease of the subject may endanger its safety or interfere with the safety assessment of the study drug. Subjects who have used CYP3A4, CYP2C9, or CYP2C19 moderately potent inhibitors or moderately potent inducers 1 week before receiving the study drug for the first time. Subjects who used CYP3A4 substrates and narrow treatment window 1 week before the first study drug.
引自 ClinicalTrials.gov, NCT03917043, 参与标准,读取于 2026年11月10日。
这些信息从哪里来
登记记录
ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT03917043,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。
疾病与医院
本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义
没有收录的内容
登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。